TPC-056

TPC-056 is an investigational drug candidate developed by Tetra Pharm Technologies for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Nonalcoholic Steatohepatitis (NASH). The drug is currently in the discovery to pre-clinical stage of development. While specific mechanistic details have not been publicly disclosed, Tetra Pharm Technologies specializes in the development of therapeutics that modulate the endocannabinoid system (ECS) and utilizes proprietary drug delivery technologies, such as Encap-S, to enhance the bioavailability and efficacy of its compounds. TPC-056 is part of the company's metabolic disease pipeline, which aims to leverage ECS pathways to address liver inflammation and fibrosis associated with MASH.